Clinical Trials
31 trialsEvaluation of a Cancer Lysate Vaccine and Montanide (Registered Trademark) ISA-51 VG With or Without the IL-15 Super-Agonist N-803 as Adjuvant Therapy for PD-L1 Negative Non-Small Cell Lung Cancer
National Institutes of Health Clinical Center (CC)
Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma
National Institutes of Health Clinical Center (CC)
PINNACLE
Spectrum Pharmaceuticals, Inc
Testing the Addition of Radiation Therapy to the Usual Treatment (Immunotherapy With or Without Chemotherapy) for Advanced Stage Non-small Cell Lung Cancer Patients Who Are PD-L1 Negative
National Cancer Institute (NCI)
Wondercel-UWD3
Wondercel Biotech (ShenZhen)
A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers
M.D. Anderson Cancer Center
PANDA-VAC
UNC Lineberger Comprehensive Cancer Center
A Trial of ChAdOx1 and MVA Vaccines Against MAGE-A3 and NY-ESO-1
Cancer Research UK
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
H. Lee Moffitt Cancer Center and Research Institute
TOP 2301: Neoadjuvant Chemo for NSCLC
Duke University
Adaptive SBRT Plus Chemoimmunotherapy for ES-SCLC
University of Maryland, Baltimore
Biodistribution&Pharmacokinetic of Position Emission Tomography(PET) Radiopharmaceutical 18F C SNAT4
Stanford University
A Phase 1 Study Evaluating the Safety, Tolerability and Efficacy of AMG 119 in Subjects With RR SCLC
Amgen
JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway Mutations
JS InnoPharm, LLC
A Study of NPX267 for Subjects With Solid Tumors Known to Express HHLA2/B7-H7
NextPoint Therapeutics, Inc.
RIM
Centre Integre Universitaire de Sante et Services Sociaux du Nord de l'ile de Montreal
PROS-CONS
National Institute for Tuberculosis and Lung Diseases, Poland
A Study of Gene Edited Autologous Neoantigen Targeted TCR T Cells With or Without Anti-PD-1 in Patients With Solid Tumors
PACT Pharma, Inc.
Lung Cancer Rehabilitation After Medical Treatment
Nantong University
A Study of Famitinib in Patients With Advanced Non-squamous and Non-Small Cell Lung Cancer (NSCLC)
Jiangsu HengRui Medicine Co., Ltd.
Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment
Oshadi Drug Administration
Phase II/Pilot Study of 2nd Generation Anti-CEA Designer T Cells in Adenocarcinomas
Roger Williams Medical Center
REALME
National Guard Health Affairs
TAXIS01
National Guard Health Affairs
REMNANT
European Organisation for Research and Treatment of Cancer - EORTC
Epidermal Growth Factor Receptor (EGFR) Status Based Gefitinib Neoadjuvant Therapy in Non Small Cell Lung Cancer (NSCLC)
Tianjin Medical University Cancer Institute and Hospital
Increased Dose of Icotinib in Advanced None Small Cell Lung Cancer Patients After Routine Gefitinib Therapy
Betta Pharmaceuticals Co., Ltd.
Panitumumab Plus Pemetrexed and Cisplatin (PemCisP) Versus PemCis in the First-line Treatment of Patients With Non-small Cell Lung Cancer
WiSP Wissenschaftlicher Service Pharma GmbH
A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies
GlaxoSmithKline
Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Gemcitabine-Cisplatin in Clinical Early Stages of Non-small Cell Lung Cancer
King Faisal Specialist Hospital & Research Center
Adjuvant Celecoxib in Completely Resected pN1-2 NSCLC Patients
Medical University of Gdansk